|Bid||84.50 x 1100|
|Ask||87.29 x 1100|
|Day's Range||85.59 - 90.65|
|52 Week Range||12.36 - 189.89|
|Beta (5Y Monthly)||1.62|
|PE Ratio (TTM)||9.74|
|Earnings Date||May 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||89.00|
In this Motley Fool Live video recorded on April 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss which stocks could be the biggest losers from this trend. Keith Speights: Now I came across another story recently, and in some ways it's surprising. While increasingly more Americans are receiving COVID-19 vaccines, the rates of COVID testing are falling pretty significantly in the United States.
In a perfect world, companies classified as growth stocks would steadily improve their sales and earnings year after year, making no amount too expensive for their stock price. Such forward-looking risks aren't really present in past financial data, so many investors are surprised once a growth stock's sales fall off a cliff. Two such companies that are currently facing this potential future are Coinbase (NASDAQ: COIN) and Fulgent Genetics (NASDAQ: FLGT).
Fulgent Genetics' (NASDAQ: FLGT) CEO Ming Hsieh made one of these on the company's fourth quarter call in March. With those two pieces of information, let's explore a few of the companies Fulgent Genetics might buy. Ming Hsieh has some experience making deals.